Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, 6020 Innsbruck, Austria.
Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, 6020 Innsbruck, Austria.
J Diabetes Complications. 2021 Jul;35(7):107931. doi: 10.1016/j.jdiacomp.2021.107931. Epub 2021 Apr 16.
Cardiovascular and renal complications are a major burden for individuals with type 2 diabetes mellitus (T2DM). Besides lifestyle interventions, current guidelines recommend combination drug therapy to prevent or delay the incidence and progression of comorbidities. However, non-adherence to pharmacotherapy is common in chronic conditions such as T2DM and a barrier to successful disease management. Numerous studies have associated medication non-adherence with worse outcome as well as higher health care costs. This narrative review provides (i) an overview on adherence measures used within and outside research settings, (ii) an estimate on the prevalence of non-adherence to antidiabetic and cardiovascular drugs in T2DM, and (iii) specifically focuses on the association of non-adherence to these drugs with renal and cardiovascular outcomes.
心血管和肾脏并发症是 2 型糖尿病(T2DM)患者的主要负担。除了生活方式干预外,目前的指南还建议联合药物治疗,以预防或延缓合并症的发生和进展。然而,在 T2DM 等慢性疾病中,药物治疗的不依从是很常见的,这也是成功管理疾病的一个障碍。许多研究表明,药物治疗不依从与较差的结果以及更高的医疗保健成本有关。本综述提供了(i)在研究内外使用的依从性措施概述,(ii)T2DM 患者对抗糖尿病和心血管药物不依从的流行率的估计,以及(iii)特别关注这些药物不依从与肾脏和心血管结果的关联。